COVID-19 UPDATE: Regenexx is committed to the health and safety of our patients. You may now be seen in clinic or via telemedicine for virtual/online or phone visits.
LEARN MORE
Our physicians are available via telemedicine to continue to give you the care you need during this difficult time. Learn more.

Further Analysis of Regenexx-C Data

By /

Receive a Regenexx® Patient Info Packet by email and learn why it's a superior regenerative solution.

By submitting the form, you are agreeing that you read and consent to our Privacy Policy. We may also contact you via email, phone, and other electronic means to communicate information about our products and services. We do not sell, or share your information to third party vendors.

Regenexx-C data

We’ve been re-analyzing Regenexx-C data for a scientific publication and came across some interesting observations. We’ve traditionally reported that hip arthritis patients tended to respond less often than knee arthritis patients to our cultured stem cell injections. However, when we take out patients with the bone disease avascular necrosis (AVN, also called osteonecrosis), a different picture emerges. AVN  is a disease where the bone in the ball of the hip joint is dying off and the arthritis is not caused by usual wear and tear forces, but usually by this bone death. While we’ve had great success in treating ARCO grade 1 and 2 AVN patients, we usually get grade 3’s and 4’s who want to try the procedure, as those patients are usually facing a hip replacement with many more possible complications than the average patient with hip arthritis. These later stage AVN patients were in our initial hip arthritis data we reported because they also have arthritis. When we remove them from that hip data at the one year mark, we see what we have above (see graph). Initially it looks like the hip arthritis patients are reporting a slightly greater amount of relief than the knee arthritis patients. However, the drop-out rate (the number of patients we couldn’t contact to obtain outcome information) is higher in the hip group than the knee group. To us, this likely still means that the patient’s with hip arthritis are not doing as well as the knee group. This is because more seem to have moved onto other treatments and as a result, are no longer answering outcome questionnaire requests. However, this data also shows that hip patients without AVN tend to do better with stem cell injections than those with AVN. We’ve been working on improvements in the procedures used to accurately place stem cells into the hip to provide maximum benefit, so hopefully the next time we look at this data the hips will be doing as well as the knees. The upshot? We spend many hours pouring through our standardized outcome questionnaires making sure what we do is helping patients and making sure that we can reasonably set expectations for any stem cell based procedure.

Is Regenexx Right For You?

Request a free Regenexx Info Packet

REGENEXX WEBINARS

Learn about the #1 Stem Cell & Platelet Procedures for treating arthritis, common joint injuries & spine pain.

Join a Webinar

RECEIVE BLOG ARTICLES BY EMAIL

Get fresh updates and insights from Regenexx delivered straight to your inbox.

Subscribe to the Blog

CONTACT US

9035 Wadsworth Pkwy #1000
Westminster, CO 80021
888-525-3005

FOLLOW US

Copyright © Regenexx 2020. All rights reserved. | Privacy Policy

*DISCLAIMER: Like all medical procedures, Regenexx® Procedures have a success and failure rate. Patient reviews and testimonials on this site should not be interpreted as a statement on the effectiveness of our treatments for anyone else.

Providers listed on the Regenexx website are for informational purposes only and are not a recommendation from Regenexx for a specific provider or a guarantee of the outcome of any treatment you receive.

LinkedIn
Email